

ASX Announcement

14 July 2026

Company Update on Clinical Development Programs Beyond Paediatric Autism

Highlights

- **Expanding beyond paediatric autism:** BlinkLab is advancing a growing pipeline of human studies beyond its registrational U.S. FDA 510(k) autism diagnostic program, targeting additional clinical and commercial opportunities.
- **Multiple upcoming catalysts:** The Company expects readouts from five study programs during CY2026, followed by five additional readouts in CY2027.
- **Addressing global unmet needs:** BlinkLab's expanding international study portfolio across North America, Europe, Africa, Australia and South America focuses on conditions where objective, scalable assessment tools remain limited.
- **Building a multi-indication platform:** These studies are designed to generate new intellectual property, validate additional clinical applications, and identify future commercial opportunities beyond BlinkLab's flagship FDA autism program.

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company") is pleased to provide an update on its expanding clinical study portfolio beyond its pivotal U.S. FDA 510(k) autism diagnostic program¹. While the Company's immediate priority remains the development and regulatory clearance of BlinkLab Dx1, it has strategically established a growing portfolio of collaborative studies designed to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions.

These studies are designed to expand the Company's intellectual property portfolio, validate new clinical applications, establish leading research collaborations, and identify new future commercial opportunities. All ten clinical development programs are exploratory in nature and are not intended to support regulatory submissions at this stage. However, positive results could pave the way for future regulatory (FDA) clinical studies to expand the range of target indications.

The studies are conducted in collaboration with academic institutions or clinical partners. In many cases, collaborators are responsible for the costs of conducting the research, participant recruitment and data collection, while BlinkLab provides access to its technology platform. Importantly, BlinkLab does not provide its regulated diagnostic product, BlinkLab Dx1. Instead, collaborators receive access to the Company's research-use online platform and research iOS app, branded as BlinkLab Cortex. This collaborative model enables the Company to efficiently expand its research footprint, generate new data and intellectual property, and evaluate multiple commercial opportunities with minimal internal investment.

¹ ASX Announcement (24 March 2026) – "BlinkLab commences Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled"

As several programs approach key milestones, BlinkLab wants to provide shareholders with greater visibility into recruitment progress, anticipated readouts and the strategic value of these initiatives. These activities complement the Company's primary objective of obtaining FDA clearance for BlinkLab Dx1, with FDA submission targeted for the end of CY2026.

Ongoing Study Portfolio and Expected Readouts

BlinkLab's study portfolio comprises ten programs spanning three strategic areas: Neurodevelopment (**Table 1**), Adult Neurology (**Table 2**), and Treatment Monitoring (**Table 3**). Recruitment is progressing well across the portfolio, with several studies approaching readout.

Table 1 Neurodevelopmental Study Programs				
Program	Collaboration	Recruitment Status	Commercial Rationale and Unmet Need	Expected Readout (CY)
Paediatric ADHD diagnostic assessment ²	Mental Care Group	375/375 (complete)	Large, high-throughput clinical market with major diagnostic bottlenecks. A scalable objective test will support faster assessment and more efficient clinical workflows.	Early Q3 2026³
Adult autism diagnostic assessment ⁴	VU Amsterdam	145/145 (complete)	Expands BlinkLab's autism opportunity beyond paediatric Dx1 into adults , including late-diagnosed individuals, with particular emphasis on women, a materially underserved diagnostic population.	Q4 2026
Adult autism and lifestyle monitoring	Erasmus MC/Internal	552 tests in 23 people (complete)	Longitudinal monitoring of sleep and stress using smartwatches and BlinkLab neurometrics. Positions BlinkLab as a lifestyle monitoring product by combining wearables with BlinkLab.	Q4 2026
Genetically defined autism ⁵	SHANK2 Foundation	17/17 (complete)	A translational research program evaluating neurometrics in both humans with SHANK2 syndrome and a SHANK2 mouse model to identify objective translational biomarkers for therapeutic development.	Q1 2027
Paediatric autism and nutrition ⁶	ESPOCH	120/300	Establishing research activity in South America, gathering real-world evidence to examine the relationship between autism-associated sensorimotor differences and nutrition .	Q2 2027
Paediatric and adult autism & ADHD deep phenotyping ⁷	Monash University	105/150	Positions BlinkLab in differential diagnosis, comorbidity profiling and personalised care across overlapping autism and ADHD presentations.	Q2 2027

Table 1. Summary of BlinkLab's six neurodevelopmental study programs, including collaboration partners, recruitment progress, commercial rationale and expected timing of study readouts. Programs are presented in chronological order based on expected readout.

² ASX Announcement (30 July 2024) - "BlinkLab partners with Mental Care Group in Europe to improve and accelerate the diagnostic evaluation of ADHD"

³ ASX Announcement (26 June 2024) - "BlinkLab Provides Update on European ADHD Study"

⁴ ASX Announcement (19 March 2025) - "Blinklab Expands Autism Diagnostics into Adults Through a New Collaboration with VU Amsterdam and NAR".

⁵ ASX Announcement (13 March 2026) - "Partnership with SHANK2 Autism Foundation in the United States".

⁶ ASX Announcement (16 June 2026) - "BlinkLab Partners with ESPOCH on Large-Scale Multicenter Ecuador Autism and Sensorimotor Study Program".

⁷ ASX Announcement (13 November 2024) - "BlinkLab to Participate in the Landmark Monash University Autism/ADHD MAGNET Project".

Table 2 | Adult Neurology Study Programs

Program	Collaboration	Recruitment Status	Commercial Rationale and Unmet Need	Expected Readout (CY)
Early dementia detection ⁸	Erasmus MC	224/250	Study on earlier and more accurate detection of Alzheimer's and frontotemporal dementia, particularly before symptoms are captured by conventional clinic-based tools.	Q4 2026
Spinocerebellar ataxia ⁹	Columbia University	42/80	Creates a pathway into remote biomarkers for motor learning, neuroplasticity and interventional studies in high-burden neurological disease .	Q1 2027

Table 2. Overview of BlinkLab's two adult neurology study programs on dementias, including Alzheimer's and frontotemporal dementia, and spinocerebellar ataxia. The table summarises each collaboration, recruitment status, commercial rationale and expected study readout. Programs are ordered according to the expected readout date.

Table 3 | Pharmacological Treatment Monitoring Study Programs

Program	Collaboration	Recruitment Status	Commercial Rationale and Unmet Need	Expected Readout (CY)
Pharma intervention with ketamine ¹⁰	Monash University	37/37 (complete)	Tests whether BlinkLab can measure pharmacological effects, supporting potential treatment-response monitoring and digital endpoints.	Q4 2026
Pharma intervention ¹¹	Erasmus MC	1/25	Demonstrates potential use in therapy evaluation and treatment monitoring for biologically defined neurodevelopmental conditions and rare-disease pharma programs.	2H 2027

Table 3. Overview of BlinkLab's two pharmacological treatment monitoring study programs. The table summarises each collaboration, recruitment status, commercial rationale and expected study readout. Programs are ordered according to the expected readout date.

A Disciplined Platform Strategy

BlinkLab's broader study portfolio follows a capital-efficient collaboration model. Academic institutions and healthcare providers contribute clinical expertise, patient access and data collection, while BlinkLab provides its technology and scientific support. BlinkLab does not provide its regulated diagnostic product BlinkLab Dx1; collaborators gain access to the Company's research-use online platform and research iOS app, enabling scientific research, technology validation and exploration of new clinical applications. This research tool, online research portal and research app, is branded as BlinkLab Cortex.

⁸ ASX Announcement (5 June 2024) - "BlinkLab to participate in a clinical study on early diagnosis of dementia in partnership with Erasmus University Medical Center".

⁹ ASX Announcement (24 July 2024) - "Study with Columbia University on Spinocerebellar Ataxias".

¹⁰ ASX Announcement (6 August 2024) - "The Pharmacology of Human Decision Making Study with Monash University".

¹¹ ASX Announcement (19 May 2026) - "BlinkLab Expands into Therapy Evaluation for Neurodevelopmental Conditions with Erasmus MC".

Each study is selected using three criteria: (1) it addresses an important unmet clinical need; (2) it has the potential to generate new intellectual property and commercial opportunities; and (3) it is supported by existing scientific evidence from conventional laboratory-based neurometric research.

Building on Established Neuroscience

BlinkLab's platform delivers precisely controlled auditory and visual stimuli through a smartphone while using computer vision and artificial intelligence to quantify subtle reflex-based responses. These neurometric assessments have been studied for decades across neuroscience, psychiatry and neurology using specialised laboratory equipment, with well-established biological mechanisms. Rather than pursuing speculative science, BlinkLab is translating these validated laboratory paradigms into a scalable smartphone platform capable of collecting objective neurometric data in larger and more clinically representative populations. Previous laboratory studies have demonstrated promising findings in many of the conditions being investigated, including ADHD, dementia, schizophrenia and genetically defined neurodevelopmental disorders.

Combining BlinkLab with Other Technologies

BlinkLab also sees significant opportunities to integrate its smartphone-based neurometric platform with complementary technologies such as EEG and wearable sensors. These multimodal approaches may further expand applications in diagnostics, treatment monitoring, digital biomarkers and personalised healthcare.

Commercial Significance

BlinkLab believes its expanding study portfolio represents a significant long-term opportunity beyond its flagship paediatric autism program. Collectively, these studies are designed to validate the broader applicability of the Company's smartphone-based neurometric platform across diagnostics, treatment monitoring and digital health. As study results become available, BlinkLab will evaluate which indications offer the strongest scientific, regulatory and commercial potential for further development, strategic partnerships and future commercialisation.

Dr Henk-Jan Boele, Managing Director and CEO, stated: *"Our first commercial priority remains obtaining FDA clearance for BlinkLab Dx1 in the United States. At the same time, we believe the long-term opportunity for BlinkLab extends well beyond a single product. Our platform enables us to deliver a broad range of well-established neurometric assessments through a smartphone, making it possible to collect objective data at a scale that has not previously been practical using conventional laboratory equipment."*

We are deliberately focusing on conditions where decades of neuroscience research have already established a strong biological foundation. Rather than starting from scratch, we are translating proven laboratory paradigms into a scalable smartphone platform that can validate these findings in larger and more clinically representative populations. We believe this approach allows us to efficiently identify new clinical applications and future commercial opportunities.

We are also encouraged by broader trends in digital health, including wearable technologies, longitudinal monitoring and personalised healthcare. BlinkLab's platform complements these developments by

providing structured, objective neurobehavioural assessments that have the potential to support diagnosis, treatment monitoring and future digital biomarkers.

What excites us is the growing interest from leading researchers, healthcare providers and patient organisations, as well as increasing interest in treatment monitoring and therapeutic development. Recognition from organisations such as SFARI and Mental Care Group reinforces our belief that objective, scalable neurometric assessment has an important role to play in the future of neuroscience and digital health."

Growing Scientific and Commercial Momentum

Since its ASX listing, BlinkLab has continued to expand its network of academic, clinical and research collaborations across North America, Europe, Australia and South America. The Company's smartphone-based neurometric platform is increasingly being adopted by leading research institutions, clinicians, healthcare providers and patient advocacy organisations seeking scalable, objective measures of sensory processing, neurodevelopment and brain function. Importantly, BlinkLab's work is receiving growing recognition beyond the traditional academic environment. During the past year, the Company's research and collaborations have been featured by organisations including the Simons Foundation Autism Research Initiative (SFARI)¹², one of the world's leading autism research organisations.

See, for example:

<https://www.sfari.org/2026/05/11/unbiased-approaches-to-quantifying-motor-and-other-visible-behaviors-in-humans-with-autism/>.

Outlook

BlinkLab remains focused on execution of its pivotal U.S. FDA 510(k) autism diagnostic program, with submission targeted for the end of CY2026. In parallel, the Company expects a steady cadence of study readouts across paediatric ADHD, adult autism, dementia, and other neurological disorders, and treatment monitoring.

These studies are expected to further evaluate the broader applicability of BlinkLab's smartphone-based neurometric platform and help identify future opportunities for commercial development, strategic partnerships and additional clinical applications.

BlinkLab believes the convergence of digital health, wearable technologies and objective neurological assessment continues to create significant opportunities for scalable neurometric biomarkers.

This announcement has been authorised for release by the Board of BlinkLab Limited.

¹² ASX Announcement (23 January 2026) – "BlinkLab Invited to Present at Simons Foundation Autism Research Initiative (SFARI) Event"

For further information please contact:

Dr Henk-Jan Boele

Managing Director & CEO

henkjan@blinklab.org

M: +31 (0) 611 132 247

Brian Leedman

Non-Executive Chairman

brian@blinklab.org

M: +61 (0) 412 281 780

About BlinkLab Limited

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx 1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.